Real-World Immunosuppressant Treatment Patterns for Patients with Lupus Nephritis in the United States.

Abstract

Lupus nephritis (LN) treatment aims to control and prevent flares and irreversible kidney damage. Around 30% of patients are unresponsive to treatment; however, real-world LN treatment patterns have not been reported. Objectives of this retrospective cohort study (GSK 209758) were to quantify the time to switching/re-initiating induction therapy in patients with LN initiating immunosuppressant therapy and conversion from induction to maintenance immunosuppressant therapy, and to assess corticosteroid use. Patients with LN initiating induction or maintenance immunosuppressant therapy were identified using claims data. Patients were followed up from the index date (immunosuppressant initiation date) until treatment discontinuation, death, disenrollment, administrative censoring, or the end of follow-up period. The cumulative incidence of switching/re-initiating induction therapy and conversion to maintenance therapy was estimated using outpatient pharmacy claims and procedure codes. Corticosteroid use was estimated using pharmacy claims; a mean daily dose of ≥ 7.5mg/day was considered high. In total, 5000 patients with LN contributed 5516 treatment episodes (induction cohort, N = 372; maintenance cohort, N = 5144). In the induction cohort, the cumulative incidence (95% confidence interval) of switching between induction therapies was 24.6% (20.1-30.0) at 12months, while 59.6% (52.4-66.1) of patients converted to maintenance therapy at 12months. In the maintenance cohort, 21.2% (19.9-22.5) re-initiated induction therapy at 12months. Oral corticosteroid use decreased during the follow-up in both cohorts, but 21.5% of patients remained on a high dose at 12months in the induction cohort, while 15.8% in the maintenance cohort were taking a high dose at 24months. Around a quarter of patients with LN initiating immunosuppressant therapy switched within 12months, while a fifth re-initiated induction therapy within 12months. Use of high corticosteroid doses were observed during 24months of follow-up. These data suggest that many patients do not respond to existing standard LN therapies.